Paul, Weiss is advising Eli Lilly and Company in its acquisition of Calytrix Bio, Inc., a biotechnology company developing precision therapies for patients with myeloproliferative neoplasms. Under the terms of the agreement, Calytrix shareholders could receive up to $1.5 billion in cash, consisting of an upfront payment and additional payments upon the achievement of certain clinical and regulatory milestones. The acquisition will add Calytrix’s lead preclinical program, which is being developed to treat essential thrombocythemia and myelofibrosis, to Lilly’s portfolio.
The Paul, Weiss team is led by corporate partners Krishna Veeraraghavan and Chelsea Darnell and intellectual property partner Jeffrey Osterman, and includes corporate counsel Gurjot Kaur; antitrust partners Jesse Solomon, Lauren O'Brien and Todd Hahn; intellectual property partners John Patten and Meggin Bednarczyk; executive compensation partners Matthew Friestedt and Sally Ye; tax partner Scott Sontag; and litigation partner Nicole Succar, and counsel Audrey Paquet and Joshua Thompson.
Related Insights
November 16, 2026
Paul, Weiss Adds Leading M&A Partner in New York
November 16, 2026